Roche Completes Acquisition Of Telavant From Roivant, Including Rights To Novel Tl1A Directed Antibody (Rvt-3101) For The Treatment Of Inflammatory Bowel Disease
Acquiring Company
Roche
Acquired Company
Telavant
Basel
New YorkOtherBiotechnologyBiotechnology ResearchDescription
Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, on an as-converted basis. An additional payment of $150 million in cash is payable upon the completion of a near-term milestone.
Quick answer
Roche is acquiring Telavant, announced December 14, 2023. Roche is based in Basel, Basel City, Switzerland.
- How much did Roche pay for Telavant?
- The deal value was not disclosed.
- What does Roche do?
- Roche Diagnostics is a global leader in in vitro diagnostics and a pioneer in personalized healthcare.
- Where are Roche and Telavant based?
- Roche is based in Basel, Basel City, Switzerland. Telavant is based in New York, New York, United States.
- Who are the decision-makers at Roche?
- Fundz holds 1 contact at Roche. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bruker Announces Agreement to Acquire Chemspeed (January 25, 2024)
- Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio (January 23, 2024)
- Oncodesign Services, a Leading European CRO In Preclinical Drug Discovery Acquires ZoBio, A CRO Specialized in Small Molecule Drug Discovery (January 23, 2024)
- Natera Acquires Reproductive Health Assets from Invitae (January 22, 2024)
- Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales (January 22, 2024)
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (January 18, 2024)
Who to call at Roche, and when
When Roche changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Roche raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Roche, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Roche. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Roche makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Telavant?
Telavant was acquired by Roche, based in Basel. The deal was reported on December 14, 2023. Roche Diagnostics is a global leader in in vitro diagnostics and a pioneer in personalized healthcare. The company develops innovative diagnostic solutions that enable better patient care. Roche is privately held and operates in Other.
When did Roche acquire Telavant?
Roche's acquisition of Telavant was reported on December 14, 2023. Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Telavant do?
Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. It is privately held, operating in Biotechnology Research, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.